Apoptosis control and proliferation marker in human normal and neoplastic adrenocortical tissues

od Bernini, G P, Moretti, A, Viacava, P, Bonadio, A G, Iacconi, P, Miccoli, P, Salvetti, A
Wydane 2002

P53 mutations in breast and ovarian carcinomas from BRCA1 and 2 mutation carriers and noncarriers

od Sensi, E, Ghimenti, C, Cipollini, G, Iandolo, D, Naccarato, G, Viacava, P, Bevilacqua, G, Caligo, MA
Wydane 2000

Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment

od Cetani, F., Pardi, E., Ambrogini, E., Banti, C., Viacava, P., Borsari, S., Bilezikian, J.P., Pinchera, A., Marcocci, C.
Wydane w J Endocrinol Invest (2008)

Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology

od Carpi, A, Naccarato, A G, Iervasi, G, Nicolini, A, Bevilacqua, G, Viacava, P, Collecchi, P, Lavra, L, Marchetti, C, Sciacchitano, S, Bartolazzi, A
Wydane 2006

Mutation Analysis of BRCA1 and BRCA2 in Italian Hereditary and Sporadic Forms of Breast and Ovarian Cancers: Tumor Genotype-Phenotype Correlation in Breast Cancer BRCA-Mutation Car...

od Cipollini, G., Ghimenti, C., Sensi, E., Iandolo, D., Piccirilli, A., Berti, A., Naccarato, G., Viacava, P., Campani, D., Bevilacqua, G., Caligo, M. A.
Wydane 1999

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib

od Bocci, G, Falcone, A, Fioravanti, A, Orlandi, P, Di Paolo, A, Fanelli, G, Viacava, P, Naccarato, A G, Kerbel, R S, Danesi, R, Del Tacca, M, Allegrini, G
Wydane 2008

Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study

od Conte, P F, Donati, S, Gennari, A, Guarneri, V, Orlandini, C, Rondini, M, Roncella, M, Marini, L, Collecchi, P, Viacava, P, Naccarato, A G, Degli Esposti, R, Bonardi, S, Bottini, A, Saracchini, S, Tumolo, S, Gullo, G, Santoro, A, Crino, L
Wydane 2005